Physician profile
Alan Graff
NPI 1669471090
$3,276.86
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,703 · 2020: $795 · 2021: $503 · 2022: $277.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $628.01 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $548.30 | 2019-2021 | |
| Novo Nordisk INC | $503.46 | 2019-2022 | |
| Amgen INC. | $264.02 | 2019-2022 | |
| Lilly USA, LLC | $193.55 | 2019-2021 | |
| Amarin Pharma, INC. | $191.85 | 2019-2022 | |
| Pfizer INC. | $185.18 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.81 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $109.77 | 2019-2022 | |
| Abbvie INC. | $107.62 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.22 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $65.17 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $50.51 | 2019-2022 | |
| Astellas Pharma US INC | $44.12 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $25.71 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $20.60 | 2021 | |
| Eisai INC. | $18.96 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $18.90 | 2021 | |
| Glaxosmithkline, LLC. | $17.99 | 2021 | |
| Acerus Pharmaceuticals Corporation | $17.98 | 2022 | |
| Corcept Therapeutics | $13.85 | 2019 | |
| Aytu Biopharma, INC. | $12.60 | 2019 | |
| Allergan, INC. | $12.00 | 2020 | |
| Gilead Sciences, INC. | $11.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Graff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.